BIO Investor Forum 2016 Programming Announced

October 18-19 Meeting in San Francisco to Feature Fireside Chats, Partnering, Panel Discussions and Company Presentations

WASHINGTON--(BUSINESS WIRE)--The Biotechnology Innovation Organization (BIO) today announced programming for the 15th annual BIO Investor Forum. Held on October 18-19 at the Westin St. Francis Hotel in San Francisco, the BIO Investor Forum explores global investment trends and opportunities in life sciences. Early and mid-stage private as well as emerging public companies poised for growth in 2017 are the focus of the event.

“We are pleased to once again offer programming for investors and companies alike with two full days designed to propel partnerships that may lead to medical breakthroughs we never imagined possible”

“We are pleased to once again offer programming for investors and companies alike with two full days designed to propel partnerships that may lead to medical breakthroughs we never imagined possible,” said BIO President and CEO Jim Greenwood. “The forum will feature fireside chats hosted by industry leaders, panel discussions on industry trends, company presentations from innovative firms and individual partnering meetings between biopharma executives and investors. This event offers enormous opportunities for both the companies poised for growth and the investors looking for favorable prospects.”

The BIO Investor Forum has continued to grow since its start in 2001 as a component of the larger BIO International Convention. The conference has expanded to include content rich programming, the SPARK showcase, company presentations, the “Buzz of BIO” contest, fireside chats and the proprietary BIO One-on-One™ Partnering™.

In addition to Fireside Chats with Rachel Haurwitz, PhD, CEO, Caribou Biosciences, Liam Ratcliffe, MD, PhD, Managing Director, New Leaf Venture Partners and Ryan Watts, PhD, CEO, Denali Therapeutics, this year’s therapeutic and business panel topics will range from the highly visible and groundbreaking CRISPR technology, to the impact of the presidential campaign on the biotech sector. These sessions are joined by others that tap into subjects like the flow of capital in the public and private marketplace, how to address inflammation caused by immuno-oncology treatments seen in clinical trials and navigating gene therapy treatments toward approval. The entire program can be viewed on the BIO Investment Forum website.

Nearly 150 company presentations by senior-level executives are expected this year to showcase their pipelines, R&D activities, and investment goals before an audience of public and private equity investors, research analysts, investment bankers and industry executives. The list of companies—updated regularly—is available on the website.

Advance media registration is now available for qualified reporters working full time for print, broadcast and web publications with valid press credentials.

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Upcoming BIO Events

BIO Animal Biotech Summit
September 21-23, 2016
Bethesda, MD

BIO Investor Forum
October 18-19, 2016
San Francisco, CA

BIO Latin America Conference
October 26-28, 2016
Grand Hyatt São Paulo, Brazil

BIO Patient and Health Advocacy Summit
November 3-4, 2016
Washington, DC


Biotechnology Innovation Organization (BIO)
Theresa Brady, 202-962-9235
Twitter: @IAmBiotech

Back to news